menu
techminis

A naukri.com initiative

google-web-stories
Home

>

Startup News

>

Mosanna Th...
source image

SiliconCanals

1M

read

403

img
dot

Image Credit: SiliconCanals

Mosanna Therapeutics raises €70.1M to disrupt sleep apnea treatment with nasal spray

  • Mosanna Therapeutics has raised €70.1M in Series A funding led by Pivotal bioVenture Partners and EQT Life Sciences, with other investors including Forbion and Norwest.
  • The funding will support the development of MOS118 through Phase 2 and the expansion of Mosanna's pipeline in sleep apnea treatment.
  • David Weber, Ph.D., has been appointed as the new CEO of Mosanna, bringing over 30 years of experience in biotech leadership to the company.
  • Mosanna Therapeutics aims to revolutionize the treatment of obstructive sleep apnea with its drug-based nasal spray alternative, MOS118, targeting upper airway muscles.

Read Full Article

like

24 Likes

For uninterrupted reading, download the app